TY - JOUR T1 - Characterizing Two Outbreak Waves of COVID-19 in Spain Using Phenomenological Epidemic Modelling JF - medRxiv DO - 10.1101/2020.12.29.20247833 SP - 2020.12.29.20247833 AU - Miguel López AU - Alberto Peinado AU - Andrés Ortiz Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/04/2020.12.29.20247833.abstract N2 - Since the first case reported of SARS-CoV-2 the end of December 2019 in China, the number of cases quickly climbed following an exponential growth trend, demonstrating that a global pandemic is possible. As of December 3, 2020, the total number of cases reported are around 65,527,000 contagions worldwide, and 1,524,000 deaths affecting 218 countries and territories. In this scenario, Spain is one of the countries that has suffered in a hard way, the ongoing epidemic caused by the novel coronavirus SARS-CoV-2, namely COVID-19 disease. In this paper, we present the utilization of phenomenological epidemic models to characterize the two first outbreak waves of COVID-19 in Spain. The study is driven using a two-step phenomenological epidemic approach. First, we use a simple generalized growth model to fit the main parameters at the early epidemic phase; later, we apply our previous finding over a logistic growth model to that characterize both waves completely. The results show that even in the absence of accurate data series, it is possible to characterize the curves of case incidence, and even construct short-term forecast in the near time horizon.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding supported this paperAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ExemtionAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the results reported in the published article can be found including, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study. https://datos.gob.es/es/catalogo/e05070101-evolucion-de-enfermedad-por-el-coronavirus-covid-19 ER -